top of page


Abeona acquires Phase III-ready ABO-801 drug assets from Ellodi in transaction worth up to $80 million plus royalties
Abeona Therapeutics has acquired the Phase III-ready eosinophilic oesophagitis candidate ABO-801 from Ellodi Pharmaceuticals in a share-based asset transaction with regulatory and commercial milestones, alongside a separate $30 million financing agreement.

nuaxia
Nov 102 min read


Dipharma acquires UK rare-disease medicines distributor LogixX Pharma
Dipharma Group has acquired longstanding UK partner LogixX Pharma, converting a decade-long rare-disease medicines distribution relationship into a directly owned British commercial operation.

nuaxia
Nov 92 min read


Avanzanite licenses Zemcelpro stem cell therapy commercialisation rights across 32 European countries
Avanzanite has secured exclusive European commercialisation rights to Cordex Biologics' conditionally authorised cord-blood stem cell therapy Zemcelpro, covering 32 countries under new licensing and supply agreements.

nuaxia
Nov 92 min read


ANI Pharmaceuticals launches $560 million recommended offer to acquire Egetis Therapeutics
ANI Pharmaceuticals has launched a recommended cash offer valued at approximately $560 million for Swedish rare-disease specialist Egetis Therapeutics, seeking to add the approved MCT8-deficiency treatment Emcitate to its portfolio.

nuaxia
Nov 62 min read


ABIONYX Pharma and OLON partner to prepare CER-001 for regulatory approval and commercial manufacturing
ABIONYX Pharma and OLON have established a strategic manufacturing partnership to support regulatory preparations and potential commercial production of CER-001.

nuaxia
Oct 82 min read


Italfarmaco licenses JCR's Phase III Hunter syndrome therapy JR-141 across US, Europe and Latin America
Italfarmaco has licensed JCR Pharmaceuticals' Phase III Hunter syndrome therapy JR-141 across the US, Europe and Latin America.

nuaxia
Oct 72 min read


CSL and Alentis sign lixudebart partnership worth up to $1.555bn plus profit share
CSL and Alentis Therapeutics have entered a global lixudebart partnership worth up to $1.555 billion, with future profits shared between the companies.

nuaxia
Oct 62 min read


Shionogi agrees $2bn acquisition of IntraBio to expand rare disease portfolio
Shionogi has agreed to acquire IntraBio for $2 billion, adding the rare neurological disease therapy AQNEURSA and its global commercial rights to the Japanese group's portfolio.

nuaxia
Oct 52 min read


FDA approves Emcitate as first treatment for MCT8 deficiency
The FDA has approved Emcitate as the first treatment for MCT8 deficiency, providing a therapy for the peripheral thyrotoxicosis associated with this ultra-rare genetic disorder.

nuaxia
Sep 291 min read


FDA approves Atebrioz for fibrodysplasia ossificans progressiva
The FDA approval adds an oral ALK2 inhibitor for patients aged 12 years and older with the ultra-rare genetic disorder fibrodysplasia ossificans progressiva.

nuaxia
Sep 282 min read


European Commission authorises Nezglyal for cerebral adrenoleukodystrophy
The EU authorisation introduces a pharmacological treatment for eligible boys with cerebral adrenoleukodystrophy under exceptional circumstances.

nuaxia
Sep 281 min read


Lexeo agrees acquisition of Mantle Therapeutics to expand Friedreich ataxia pipeline
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics for up to $21.3 million, adding four Friedreich ataxia development programmes to its pipeline.

nuaxia
Sep 232 min read


FDA approves Aqneursa as first treatment for ataxia in ataxia-telangiectasia
The FDA has approved Aqneursa as the first treatment specifically indicated for ataxia in adults and children with ataxia-telangiectasia weighing at least 15kg.

nuaxia
Sep 221 min read


FDA approves Fayuvi as first gene therapy for Sanfilippo syndrome type A
The FDA has approved Fayuvi as the first gene therapy for children with Sanfilippo syndrome type A, introducing the first treatment designed to address the underlying cause of the rare neurodegenerative disorder.

nuaxia
Sep 182 min read


FDA approves Isembyld as first muscle-targeted treatment for spinal muscular atrophy
The FDA has approved Isembyld as the first spinal muscular atrophy treatment designed to directly target muscle loss, for patients aged 2 years and older receiving an SMN2-targeted therapy.

nuaxia
Sep 142 min read


FDA approves Zanvastro as first treatment for Alexander disease
The FDA has approved Zanvastro as the first treatment for Alexander disease in paediatric and adult patients.

nuaxia
Sep 41 min read


Ireland’s HSE agrees to fund Skyclarys after Biogen improves commercial offer
The reimbursement decision clears the way for Irish patients with Friedreich’s ataxia to access the first treatment for the rare neurological disease, following prolonged negotiations over cost and clinical value.

nuaxia
Aug 272 min read


European Commission approves Daybu as first treatment for Rett syndrome in the EU
The authorisation gives patients aged five years and older the first treatment specifically approved for Rett syndrome across the European Union, with Acadia preparing for an initial German launch in the fourth quarter of 2026.

nuaxia
Aug 252 min read


European Commission grants orphan designation to Vanda’s imsidolimab for generalised pustular psoriasis
The designation provides regulatory development incentives for Vanda’s IL-36 receptor inhibitor in the EU and follows orphan status for the investigational therapy in the US and Japan.

nuaxia
Aug 252 min read


Dimerix receives US$10 million upfront payment from Everest under DMX-200 licensing agreement
The payment strengthens Dimerix's balance sheet while advancing its regional partnering strategy for the Phase III kidney disease therapy DMX-200 across Asia.

nuaxia
Aug 213 min read
bottom of page